Rebecca Araujo

DocwireNews

A post hoc analysis of the CLEAR trial, presented at the <a href="https://www.hoparx.org/hopa-learn/conferences-events/" target="_blank" rel="noopener">Hematology/Oncology Pharmacy Association Annual Conference 2024</a>, found clinically relevant efficacy of lenvatinib plus pembrolizumab compared with sunitinib as a first-line treatment for patients with advanced renal cell carcinoma.The CLEAR trial compared three regimens: lenvatinib plus pembrolizumab, lenvatinib plus everolimus, and sunitinib. For this post hoc study, lenvatinib plus pembrolizumab was compared with sunitinib in regard to tumor response, progression-free survival (PFS), and duration of response (DOR). In total, 355 patients were in the lenvatinib and pembrolizumab group and 357 patients were in the sunitinib group. The researchers compared outcomes in subgroups with baseline lung, lymph node, bone, liver, and brain metastases.In all subgroups, PFS favored the lenvatinib plus pembrolizumab group. The hazard ratio (HR) for disease progression with this regimen was 0.47 (95% CI, 0.38&ndash;0.57). The objective response rate was also greater in the lenvatinib treatment group (71.3%) compared with the sunitinib group (36.7%). The HR for response with lenvatinib and pembrolizumab versus sunitinib was 4.31 (95% CI, 3.14&ndash;5.92). The median DOR for the lenvatinib regimen was 26.7 months compared with 14.7 months with sunitinib.&ldquo;Greater depth and breadth of tumor shrinkage at nadir was observed in target lesions in specific organ sites (lung, lymph node, liver, and bone) for patients in the lenvatinib plus pembrolizumab arm versus the sunitinib arm,&rdquo; the authors noted.&ldquo;Results of this post hoc analysis further support the early, deep, and durable tumor response benefit with lenvatinib plus pembrolizumab versus sunitinib observed in the CLEAR trial,&rdquo; they concluded.<h4>Reference</h4>Gr&uuml;nwald V, McKay RR, Buchler, et al. Tumor response by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab vs sunitinib: post hoc analysis of the CLEAR trial. Poster. Presented at the Hematology/Oncology Pharmacy Association Annual Conference 2024; April 3-6, 2024; Tampa, Florida.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Lenvatinib Plus Pembrolizumab Shows Tumor Response Benefit in Advanced Renal Cell Carcinoma

HOPA Annual Conference 2024

A clinically relevant response rate was found with lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma with baseline metastasis. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe